Ipamorelin vs CJC-1295

The most-stacked pair in the peptide world — what does the evidence actually say about either?

No head-to-head trial — cross-trial comparison
In one paragraphThey work on two different switches: CJC-1295 is a long-acting GHRH analogue that raises growth hormone for days, ipamorelin is a short-acting ghrelin-receptor agonist that produces a clean pulse. CJC-1295 has the better hormone data — a single injection raised GH two- to ten-fold for six days or more. Ipamorelin has the only randomised outcome trial between them, and it was negative. Neither has ever been shown to change body composition, strength or recovery in a controlled human trial, and both are banned in sport.

Side by side

C IpamorelinC CJC-1295
LYO overall gradeCC
MechanismGhrelin / GH-secretagogue receptor agonistGHRH receptor agonist (long-acting)
Best hormone evidenceTeichman 2006, healthy adultsAcute GH rise in small early-phase studiesGH up 2–10× for 6+ days, IGF-1 up 1.5–3× for 9–11 days
Half-lifeDrug-affinity complex binds albuminAbout 2 hours5.8–8.1 days
Randomised outcome trial1 — post-operative ileus, negativeNone
Body-composition evidenceNoneNone
SelectivityHigh — little cortisol or prolactin riseHigh — acts on the GHRH receptor, preserves pulsatility
Approved anywhereNoNo
Sport (WADA)Prohibited at all times (S2)Prohibited at all times (S2)
Verdict

No head-to-head exists, and the question people are really asking — which builds more muscle — has no answer for either, because neither has been tested for it. CJC-1295 moves the hormone marker harder and for longer; ipamorelin is the more selective molecule; both stop there.

Two switches, not two strengths

The body releases growth hormone under two opposing controls: GHRH tells the pituitary to release it, and somatostatin tells it to stop. Ghrelin acts on a third receptor and amplifies the pulse. CJC-1295 is a GHRH analogue engineered to bind albumin so it lasts days instead of minutes. Ipamorelin is a ghrelin mimic that produces a sharp, short pulse and — unusually for its class — barely touches cortisol or prolactin.

That is why they are sold as a stack: in principle a GHRH analogue and a ghrelin agonist push on different levers at once. It is a reasonable pharmacological idea. It has never been tested as a combination in a controlled human trial for any outcome.

What each one actually demonstrated

CJC-1295's evidence is a 2006 early-phase study in healthy adults, and it is genuinely striking on the marker: a single injection produced dose-dependent increases in mean plasma GH of two- to ten-fold for six days or more, and IGF-1 of 1.5- to three-fold for nine to eleven days. No serious adverse reactions were reported. Development then stopped, and no trial ever measured whether that hormone change did anything.

Ipamorelin has the opposite shape of evidence: less hormone data, but one real randomised trial. It was tested in 117 bowel-surgery patients for post-operative gut recovery — a legitimate clinical question for a ghrelin agonist — and missed. Median time to tolerate a solid meal was 25.3 hours versus 32.6 on placebo, which sounds favourable until you see the p-value of 0.15. Development stopped there too.

The claim neither supports

Both are marketed for muscle, fat loss, recovery and sleep. There is no controlled human trial of either compound for any of those outcomes. Raising growth hormone is a marker, not a result: the one place a long-acting GH secretagogue has been studied properly for a clinical endpoint — ipamorelin, for gut recovery — it did not work.

This matters more than it sounds. Growth-hormone secretagogues also tend to desensitise: the closely related hexarelin's GH response fell measurably over 16 weeks of dosing and recovered only after stopping. Whether either of these does the same over months of use has not been measured.

Questions people actually ask

Is the ipamorelin + CJC-1295 stack proven?
No. Neither compound has a controlled human trial for muscle, fat or recovery, and the combination has never been tested in one at all. The rationale is pharmacological, not evidential.
Which raises growth hormone more?
CJC-1295, by a wide margin and for much longer — days rather than hours. Whether more growth hormone for longer is better, or simply more, is the question no trial has answered.
Are they legal?
Neither is an approved medicine anywhere. Both are prohibited in sport at all times under WADA category S2.

References

  1. 1
  2. 2
  3. 3
    Rahim A, et al. Growth hormone status during long-term hexarelin therapy.J Clin Endocrinol Metab, 1998;83:1644–1649Class evidence for desensitisation with continued dosing.